Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 11/20 | 0.63 |
| ▸ | TAS1R3 | Q7RTX0 | 6/20 | 0.49 |
| ▸ | TAS1R1 | Q7RTX1 | 6/20 | 0.49 |
| ▸ | TAS1R2 | Q8TE23 | 6/20 | 0.49 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3703000 | 0.88 | NAMPT (0.65) | NAMPTTAS1R3TAS1R1TAS1R2FFAR2 | |
| SCHEMBL3712841 | 0.79 | FFAR2 (0.49) | NAMPTFFAR2 | |
| SCHEMBL3701422 | 0.78 | NAMPT (1.00) | NAMPT | |
| SCHEMBL15051480 | 0.76 | OGA (0.44) | NAMPTFFAR2 | |
| SCHEMBL3580537 | 0.75 | KDR (0.61) | FFAR2 | |
| SCHEMBL3700847 | 0.74 | NAMPT (1.00) | NAMPT | |
| SCHEMBL2370331 | 0.74 | DDX3X (0.54) | FFAR2 | |
| SCHEMBL3705621 | 0.73 | NAMPT (0.66) | NAMPTTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL3705114 | 0.73 | NAMPT (0.66) | NAMPTTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL2370795 | 0.73 | FFAR2 (0.53) | FFAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10093624-B2 | NAMPT and ROCK inhibitors | ABBVIE INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-9302989-B2 | NAMPT and rock inhibitors | ABBVIE INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-20160031880-A1 | Nampt and Rock Inhibitors | ABBVIE INC. (US) | 2016-02-04 | — | — | US | disclosed |
| EP-2640698-A1 | NAMPT AND ROCK INHIBITORS | AbbVie Inc. (US) | 2013-09-25 | — | — | EP | disclosed |
| WO-2012067965-A1 | NAMPT AND ROCK INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-24 | — | — | WO | disclosed |
| US-20120122842-A1 | NAMPT AND ROCK INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10093624-B2 | NAMPT and ROCK inhibitors | NAMPT, NNMT, NADK | NAMPT 1/4885TAS1R3 3988/4885TAS1R1 4181/4885 |
| US-20120122842-A1 | NAMPT AND ROCK INHIBITORS | NAMPT, NNMT, NME2 | NAMPT 1/4885TAS1R3 4597/4885TAS1R1 4638/4885 |
| US-20160031880-A1 | Nampt and Rock Inhibitors | NAMPT, NNMT, NME2 | NAMPT 1/4885TAS1R3 4597/4885TAS1R1 4638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.